Insight

Katsuaki Maehara: Interesting indirect comparison analysis for Melanoma

Katsuaki Maehara/X

Aug 19, 2024, 11:57

Katsuaki Maehara: Interesting indirect comparison analysis for Melanoma

Katsuaki Maehara shared a post on X:

“Melanoma Journal of Clinical Oncology.

NCCN Guidelines recommended both Nivo+ Rela and Nico + Ipi as preferred, category 1, first-line systemic therapy options for unresectable or metastatic melanoma.
An interesting INDIRECT comparison analysis has been published.”

No difference in efficacy has been observed, but there are indications that Nivo + Rela tends to be better in terms of safety.

First-Line Nivolumab Plus Relatlimab Versus Nivolumab Plus Ipilimumab in Advanced Melanoma: An Indirect Treatment Comparison Using RELATIVITY-047 and CheckMate 067 Trial Data

Authors: Georgina V. Long, Evan J. Lipson, F. Stephen Hodi, Paolo A. Ascierto, James Larkin, Christopher Lao, Jean-Jacques Grob, Flavia Ejzykowicz, Andriy Moshyk3, Viviana Garcia-Horton, Zheng-Yi Zhou, Yiqiao Xin, Jennell Palaia, Laura McDonald, Sarah Keidel, Anthony Salvatore, Divya Patel, Leon A. Sakkal, Hussein Tawbi, and Dirk Schadendorf.

Source: Katsuaki Maehara/X

cancer Dirk Schadendorf eorgina V. Long Evan J Lipson F. Stephen Hodi Hussein Tawbi Journal of Clinical Oncology Katsuaki Maehara Leon A. Sakkal NCCN guidelines OncoDaily Oncology

Esophageal Cancer: Symptoms, Causes, Stages, Diagnosis & Treatment

Faster, Flexible and Affordable: Mikhail Groubman on Building a Global Legacy in Clinical Research in an Untapped Market

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Special Coverage